AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest
This article was originally published in The Pink Sheet Daily
Executive Summary
AZ will pay up to $505 million and split antibiotic cocktail rights with Novexel partner Forest, which in turn will pay more than $200 million to AZ.
You may also be interested in...
$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership
The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.